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Abstract The aim of this study was to evaluate endo-
thelial lipase (EL) protein expression in advanced human
carotid artery plaques (HCAP) with regard to plaque
(in)stability and the incidence of symptoms. HCAP were
collected from 66 patients undergoing carotid endarterec-
tomy (CEA). The degree of plaque (in)stability was esti-
mated by ultrasound and histology. In HCAP sections, EL
expression was determined by immunostaining and the
intensity was assessed on a semi-quantitative scale (low:
\25%, high: [25% positive cells). Monocytes and mac-
rophages in adjacent HCAP sections were stained with a
CD163 speciﬁc antibody. High EL staining was more
prevalent in histologically unstable plaques (in 33.3% of
ﬁbrous plaques, 50% of ulcerated non-complicated plaques
and 79.2% of ulcerated complicated plaques; v
2 test,
p = 0.004) and in the symptomatic group (70.8 vs. 42.9%
in the asymptomatic group; v
2 test, p = 0.028). The
majority of EL immunostaining was found in those HCAP
regions exhibiting a strong CD163 immunostaining. EL in
HCAP might be a marker and/or promoter of plaque
instability and HCAP-related symptomatology.
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Introduction
Atherosclerosis is a chronic ﬁbro-proliferative and immuno-
inﬂammatory disease affecting large and medium size
arteries. It is characterized by endothelial dysfunction,
local oxidation of circulating lipoproteins [particularly low
density lipoprotein (LDL)] and their accumulation in the
vascular wall [1, 2], and the activation of proinﬂammatory
cytokines [3, 4]. Inﬂammation plays a crucial role in plaque
destabilization, as it converts stable atherosclerotic pla-
ques, characterized by a ﬁbrous cap covering the necrotic
core, into unstable ones, characterized by a thinned ﬁbrous
cap, intra-plaque hemorrhage, surface ulceration, rupture
and thrombosis [5].
Endothelial lipase (EL) is a member of the triglyceride
lipase gene family, expressed by vascular endothelial cells
(ECs), smooth muscle cells (SMCs) and macrophages [6, 7].
It primarily exhibits phospholipase-A1 activity, with high
afﬁnity for high density lipoprotein (HDL)-phosphatidyl-
choline (HDL-PC), resulting in the generation of bioactive
molecules such as lysophosphatidylcholines (lyso-PC) and
free fatty acids (FFA) [8]. Acting on HDL, EL not only
promotes HDL remodeling but also lowering of HDL plasma
levels, an independent risk factor for atherosclerosis [9]. EL
plasma concentrations are strongly associated with elevated
plasma interleukin-6 (IL-6), tumor necrosis factor (TNF)-a
and C-reactive protein (CRP) levels; a proﬁle typical of
metabolic syndrome [10, 11]. EL was also shown to promote
the expression of inﬂammatory cytokines, exempliﬁed by
attenuation of inﬂammatory cytokine expression in EL-deﬁ-
cient macrophages [12] as well as by increased production of
IL-8 in human endothelial cells over-expressing EL [13].
Taking into account the role of inﬂammation in plaque
destabilization, together with the reported up-regulation of
EL under inﬂammatory conditions, we assumed a positive
relationship between the expression level of EL and the
degree of plaque instability.
Patients and methods
Patients
Patients were recruited from the Department of Vascular
Surgery, Sisters of Mercy University Hospital, Zagreb,
Croatia, between 1 November 2007 and 1 March 2009.
Written informed consent from each patient was obtained
prior to the enrollment in the study, which was performed
according to Good Clinical Practice and Helsinki Decla-
ration principles. The study was approved by the local
ethics committee, in accordance with institutional guide-
lines of the Sisters of Mercy University Hospital, Zagreb.
Inclusion and exclusion criteria
Overall, 88 patients with signiﬁcant (70–99%) carotid
artery stenosis (conﬁrmed by carotid Color Doppler Flow
Imaging (CDFI) done by an experienced physician in the
University Hospital) were screened for inclusion and
exclusion criteria. In cases where CDFI imaging was lim-
ited by features such as calciﬁed carotid lesions, tortuous or
kinked carotid arteries or patient body constitution, contrast
enhanced magnetic resonance angiography (CEMRA) or
computed tomography angiography (CTA) was performed.
The clinical indication for carotid endarterectomy (CEA)
was met after examination by the neurologist and vascular
surgeon, based on clinical presentation and CDFI (or
CEMRA/CTA) results, following guidelines for treatment
of extra-cranial carotid artery disease [14, 15]. Exclusion
criteria were met in case of acute or chronic infection or
inﬂammatory conditions (other than atherosclerosis),
severe renal failure (serum creatinine C200 mmol/L),
severe hepatic cirrhosis (Child-Pugh Class B or C), neo-
plasms, recent trauma or surgery, history of ipsilateral CEA
or radiotherapy and anticoagulant therapy. Patients with a
possible cardiac source of embolism detected through the
patients’ history, electrocardiogram or echocardiography
(left ventricular aneurysm, previous large anterior cardiac
infarction, dilatative cardiomyopathy, aneurysm of inter-
atrial septum with patent foramen ovale) were excluded
from the study.
Deﬁnition of symptomatic carotid disease
The carotid stenosis was considered symptomatic if a
patient had experienced a focal neurological symptom
(ipsilateral stroke, transient ischemic attack or monocular
blindness), sudden in onset and referable to the respective
carotid artery within 4 months of CEA.
Patient characteristics, history and medication
Medical history was recorded from all patients, and the
presence of vascular risk factors, features of metabolic
syndrome,previous antihypertensive,statin,andantiplatelet
treatments were noted. Clinical history was assessed for
diabetes mellitus, smoking, hypertension, hyperlipidemia,
prior acute myocardial infarction, symptoms of peripheral
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123vascular disease and family history of CHD or IVC in ﬁrst-
degree relatives under the age of 55 years. The body mass
index (BMI) was calculated according toQuetelet’s formula
as the ratio of body weight to body height squared (kg/m
2).
Waist circumference was measured with a ﬂexible tape,
placed on a horizontal plane at the level of the iliac crest.
Metabolic syndrome was deﬁned according to the criteria of
the International Diabetes Federation issued in 2005 (http://
www.idf.org/): increased waist circumference (for Cauca-
sian European men C94 cm, for women C80 cm) plus any
two of the following: triglycerides[1.7 mmol/L (or treat-
ment for elevated triglycerides), HDL cholesterol \1.03
mmol/L in men or\1.29 mmol/L in women (or treatment
for low HDL), systolic blood pressure [130 mmHg,
diastolic blood pressure [85 mmHg (or treatment for
hypertension), and fasting plasma glucose[5.6 mmol/L (or
previously diagnosed type 2 diabetes mellitus) .
Blood pressure was measured with mercurial sphyg-
momanometer (Riester, Jungingen, Germany) and calcu-
lated as the average of three measurements taken under
standardized conditions in a supine position. Hypertension
was diagnosed according to World Health Organization
(WHO) criteria (blood pressure C140/90 mmHg or current
anti-hypertensive treatment). Diabetes was diagnosed in
patients with dietary treatment, anti-diabetics or current
fasting plasma glucose levels higher than 7.0 mmol/L.
Hyperlipoproteinaemia was deﬁned if the low density
lipoprotein (LDL) cholesterol level was[3.5 mmol/L, or if
a patient was taking a lipid-lowering drug. According to
cigarette smoking, patients were classiﬁed as current
smokers (smoking more than ﬁve cigarettes within the past
3 months), former smokers ([3 months and\10 years) or
non-smokers.
Methods
Color Doppler Flow Imaging (CDFI)
CDFI of both carotid arteries was performed in all subjects
on admission using commercially available equipment
(Aloka 5,500 and Alfa 10 Premium with 10-MHz linear
array transducer). The grade of plaque stenosis was
assessed according to deﬁned criteria [16]. Plaques were
divided depending on the presence of the echolucency and
calciﬁcation into: (1) ﬁbrous plaques (without echolucent
material and calciﬁcation), (2) soft plaques (predominantly
echolucent material), (3) calciﬁed plaques, (4) mixed pla-
ques (both calciﬁcation and echolucent material present),
and (5) non-deﬁned plaques (ﬁbrous plaques with small
degree of echolucency and calciﬁcation). In this regard,
echolucency is considered an important factor associated
with symptomatic carotid disease [17] and plaque
vulnerability.
Tissue sampling, preservation of carotid plaque specimens
and histology
Carotid specimens were excised by the vascular surgeon
(complete tubular specimen without damage to the luminal
surface) and collected during surgery. They were imme-
diately rinsed in 0.9% saline, ﬁxed for 24 h in 5 mL buf-
fered formalin, followed by several phosphate buffered
saline (PBS) washes and storage in PBS for 2 weeks before
embedding in parafﬁn. Plaque morphology was assessed by
standard histological examination of hematoxylin and
eosin-stained (HE) sections (5 lm) and screened for fea-
tures indicative of plaque vulnerability. Taking into
account the lack of new, prospectively validated criteria for
plaque vulnerability, the Stary classiﬁcation [5] was
applied and plaques were deﬁned as: (1) ﬁbrous (F) (cov-
ered by a smooth luminal surface indicative of an intact
ﬁbrous cap), (2) ulcerated non-complicated (UNC) (thin
ﬁssured or ruptured cap), and (3) ulcerated complicated
(UC) (thin ﬁssured or ruptured cap with intra-plaque
hemorrhage and/or thrombus).
Immunohistochemistry
Formalin ﬁxed and parafﬁn embedded human carotid sec-
tions (5 lm) were mounted on Superfrost Plus slides
(Menzel, Braunschweig, Germany) and dried at 40C
overnight. Slides were dewaxed twice in xylene for 10 min
and rehydrated through a graded series of alcohol. Antigen
retrieval was performed by sequentially incubating the
slides in antigen retrieval buffer pH 9 (Eubio, Vienna
Austria) for 2 min at 720 W and 3 9 5 min at 160 W in
the microwave. Immunohistochemistry was performed
using the Ultravision LP detection system (Thermo Sci-
entiﬁc, Fremont, USA) according to the manufacturer’s
instructions. In brief, endogenous peroxidase was blocked
by incubation with Hydrogen Peroxide Block (Thermo
Scientiﬁc) for 10 min. Thereafter, slides were washed with
PBS and unspeciﬁc background was blocked with Ultra V
Block (Thermo scientiﬁc) for 8 min. Rabbit clonal anti-
human CD163 (DB Biotech, clone K20-T, diluted 1:100)
and rabbit anti-EL serum (1:1,500) [18] were diluted in
antibody diluent (DAKO) and incubated on slides for 1 h at
RT. After PBS washing steps, detection was achieved by
incubation with the UltraVision HRP-labelled polymer
system for 15 min and 3-amino-9-ethylcarbacole (AEC,
Dako, Denmark), according to the manufacturer’s instruc-
tions. For negative controls, slides were incubated with
rabbit IgG Ab-1 (2 lg/ml, Neomarkers) instead of the
primary antibodies. Nuclei were stained with hemalaun and
slides were mounted with Kaiser’s glycerol gelatine. Ima-
ges of sections were taken with an Axiophot microscope
equipped with an AxioCam HRc digital camera (Zeiss,
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123Oberkochen, Germany). Importantly, all samples were
processed simultaneously using the same batch of reagents.
The expression of EL was evaluated on a semi-quantitative
scale by three independent, experienced investigators
blinded to the clinical and histology data. The scoring was
arbitrary, as follows: (1) low staining (A) (\25% positive
cells), and (2) high staining (B) ([25% positive cells).
Assays
Blood samples for laboratory assays were obtained before
surgery at approximately 8 am, following overnight fast-
ing. Blood sampled in ethylenediaminetetraacetic acid
(EDTA)-K3 containing tubes was used for hematological
assays (Coulter-Counter S plus junior, Coulter Electornics
Limited, Luton, UK). Coagulation parameters were asses-
sed from blood samples in 3.8% sodium citrate. After
separation of plasma by centrifugation (3000g for 10 min),
the Quicktest was performed on a Behring coagulation
timer (Dade Behring, Marburg, Germany). Serum creati-
nine, bilirubin, aspartate transaminase, alanine transami-
nase, blood glucose level, total plasma cholesterol,
triglyceride, LDL and HDL were measured on automated,
multi-channel selective analyzers Olympus AU2700 and
Olympus Fractoscan junior (Olympus Diagnostica GmbH,
Hamburg, Germany). High sensitivity (hs) CRP concen-
trations were measured on automated, multichannel selec-
tive analyzer Modular (Roche Diagnostics, Mannheim,
Germany). IL-6 concentrations were measured using a
speciﬁc chemiluminescent ELISA (QuantiGlo; R&D Sys-
tems, Wiesbaden-Nordenstadt, Germany) according to the
manufacturers’ instructions.
Statistical analysis
Data were summarized using mean and standard deviation
or median, minimum, maximum as appropriate for con-
tinuous variables and counts as well as percentages for
categorical variables. Data distribution was analyzed by
Kolmogorov–Smirnov test. According to these results,
appropriate parametric or non-parametric tests were used
in further analyses. Unpaired Student’s t-test or Mann–
Whitney U test was performed to assess differences
among quantitative variables between symptomatology and
immunohistochemistry groups. Differences between ordi-
nally scaled histological groups were analyzed with Krus-
kal–Wallis test, whereas Chi square test was applied to
analyze differences in qualitative and categorical variables.
The association between quantitative data was evaluated
using Spearman-rank correlation analysis. Data were
analyzed using PASW 17.02 (IBM, Chicago, IL, USA)
software and all p values below 0.05 were considered
signiﬁcant.
Results
Sample size and clinical characteristics
Out of 88 patients assessed for eligibility, 22 patients were
excluded (see Fig. 1). The ﬁnal study population included
66 patients (43 males and 23 females, mean age 67.5 years)
stratiﬁed into two groups: the asymptomatic group (42 pts)
and the symptomatic group (24 pts). The patients’ clinical
characteristics and medications are shown in Table 1. The
two groups did not differ signiﬁcantly according to age,
gender, individual risk factors, medication, or coexistence
of other vascular diseases (peripheral vascular disease, past
myocardial infarction, angina pectoris). In the symptomatic
group, however, a higher incidence of patients with
increased waist circumference was found (62.5 vs. 38%; v
2
test, p = 0.049). The BMI was also higher in the symp-
tomatic group (28.2 ± 3.0 vs. 26.8 ± 3.0) but the differ-
ence did not reach statistical signiﬁcance (p = 0.085).
Overall, there was no signiﬁcant difference in the number
of metabolic risk factors. Basic biochemical and hemato-
logical parameters as well as inﬂammatory parameters
(WBC, hs-CRP, erythrocyte sedimentation rate, ﬁbrinogen
and IL-6) did not differ between the groups (Table 2).
Fig. 1 Flow chart of the study
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The grade of carotid artery stenosis detected by CDFI (or
CEMRA/CTA) was considerably higher in the symptom-
atic group (v
2 test, p = 0.027) (Table 3). Additionally,
plaques with morphologic characteristics suggestive of
plaque vulnerability (echolucent zones with or without
ulcerated morphology) seen on CDFI were more frequent
in the symptomatic group (v
2 test, p = 0.039). Finally, the
majority of asymptomatic plaques (50%) were F plaques,
whereas the majority of symptomatic plaques (50%) were
UC plaques (not statistically signiﬁcant) (Table 3).
EL immunostaining in plaques
In F plaques (Fig 2a–c), the necrotic core was covered with
a ﬁbrotic cap with preserved endothelium and only few
inﬂammatory cells (Fig. 2a). In UC plaques (Fig. 2d–e), in
contrast, the necrotic core was covered with inﬂammatory
inﬁltrates, composed of lymphocytes, macrophages, sid-
erophages and importantly of erythrocytes, indicating intra-
plaque hemorrhage (Fig 2d). In F plaques, a weak EL
immunostaining (type A) was detected in the endothelial
layer and in the ﬁbrous cap (Fig. 2b). The ﬁbrous cap also
exhibited moderate CD163 immunostaining, indicative of
the presence of monocytes and macrophages (Fig. 2c).
Compared with F plaques, EL staining was more pro-
nounced (type B) in UC plaques (Fig. 2e). Here, EL
staining localized primarily to cells of the inﬂammatory
inﬁltrate (Fig. 2e), which showed a strong staining for
CD163 as well (Fig. 2f).
Importantly, high intensity EL immunostaining (type B)
was most frequently observed in UC plaques (79%; 19 of
24 pts), followed by UNC and F with 50% (6 of 12 pts) and
33% (10 of 30 pts), respectively (Fig. 3)( v
2 test,
p = 0.004). Furthermore, EL immunostaining type B was
Table 1 Clinical characteristics
and patient medications at the
enrollment into the study
BMI body mass index, ACE
angiotensin-converting enzyme
a Familiar history of
cardiovascular disease or stoke
in ﬁrst relatives younger than
55 years
 Fisher exact test, p = 0.049
Clinical characteristic and medications Asymptomatic (n = 42)
(mean ± SD)
Symptomatic (n = 24)
(mean ± SD)
Age (years; median, range) 69 (43–83) 65.5 (50–84)
BMI (kg/m
2; mean ± SD) 26.8 ± 3.0 28.2 ± 3.0
Waist circumference (cm; mean ± SD) 91.6 ± 7.51 94.1 ± 8.5
No. of patients (%)
Gender
Men 28 (66.6) 15 (62.5)
Women 14 (33.3) 9 (37.5)
Increased waist circumference
 16 (38.1) 15 (62.5)
Cardiovascular risk factors
Arterial hypertension 36 (85.7) 22 (91.6)
Hyperlipoproteinaemia 31 (73.8) 21 (87.5)
Diabetes mellitus or glucose intolerance 20 (47.6) 15 (62.5)
Tobacco (current or recent) 16 (38.0) 14 (58.3)
Family history
a 9 (21.4) 4 (16.7)
Peripheral vascular disease 21 (50.0) 9 (37.5)
Coronary artery disease 12 (28.5) 6 (25.0)
Medications
Statins 29 (69.0) 16 (66.6)
ACE inhibitors 21 (50.0) 12 (50.0)
Angiotensin receptor blockers 7 (16.6) 3 (12.5)
Calcium channel blockers 19 (45.2) 8 (33.3)
Acetyl salicylic acid 25 (59.2) 19 (79.1)
No. of metabolic elements present
0 3 (7.1) 1 (4.2)
1 4 (9.5) 2 (8.3)
2 15 (35.7) 5 (20.8)
3 8 (19.0) 4 (16.7)
4 9 (21.4) 11 (45.8)
5 3 (7.1) 1 (4.2)
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123signiﬁcantly more prevalent in plaques of symptomatic
patients (Table 3)( v
2 test, p = 0.028). Inﬂammatory
markers (IL-6 and hsCRP) as well as HDL plasma levels
were comparable between patients with EL immunostain-
ing type A and B (Mann–Whitney U test, p = 0.17 for IL-
6; p = 0.44 for hsCRP; p = 0.76 for HDL).
Discussion
The major ﬁndings of the present study are: (1) higher EL
immunostaining in unstable HCAP and (2) higher EL
immunostaining in plaques of patients exhibiting HCAP—
related symptomatology. Probably the main connector
between plaque stability, inﬂammation and EL are mac-
rophages, which play an important role in plaque destabi-
lization [19]. Using immunohistochemistry, Azumi et al.
[20] identiﬁed macrophages and smooth muscle cells as
main source of EL in HCAP. This was conﬁrmed by a
Danish study [21], which detected EL mRNA and protein
in areas between the ﬁbrotic cap and the necrotic core, co-
localizing primarily with macrophage speciﬁc CD68;
however, that study exclusively included symptomatic
carotid patients (26 pts). In the present study, the intensity
of both EL and CD163 immunostaining increased with
plaque instability, however not all CD163 positive regions/
cells were positive for EL staining. This might be
explained by the fact that CD163 (a scavenger receptor for
haptoglobin/hemoglobin complexes) is expressed by both
monocytes and macrophages [22], whereas EL protein
expression is negligible in monocytes but prominent in
macrophages and foam cells [21]. Accordingly, the up-
regulation of EL (in plaque macrophages) might aggravate
inﬂammation by promoting cytokine production [12, 13]o r
LDL uptake [23, 24].
Most studies, addressing EL in the context of inﬂam-
mation and atherosclerosis, were based on the plasma
levels of EL. In healthy subjects with a family history of
premature coronary heart disease (CHD), increased plasma
EL concentrations were associated with subclinical CHD
[10]. Badelino et al. [25] reported increased plasma EL
levels under experimental endotoxemia and in patients with
metabolic syndrome, a known proinﬂammatory condition.
In the present study, where all patients exhibited
advanced atherosclerotic lesions in at least one (target)
artery, inﬂammatory serum markers, such as IL-6 and
hsCRP, were not different between patients with low and
high EL expression in HCAP (Mann–Whitney U test,
Table 2 Patient blood parameters at the enrollment in the study
Parameter Asymptomatic
(n = 42)
(mean ± SD)
Symptomatic
(n = 24)
(mean ± SD)
Platelets (910
9/L) 237 ± 67 219 ± 52
Hemoglobin (g/L) 137.8 ± 14.1 140.5 ± 9.1
WBC (910
9/L) 8.21 ± 2.4 7.33 ± 1.65
Fibrinogen (g/L) 4.28 ± 0.86 4.62 ± 1.02
APTT (s) 25.2 ± 4.6 26.4 ± 3.4
PT (%) 104.3 ± 11.8 103.6 ± 8.9
ESR (mm/h) 18.5 ± 8.7 19.2 ± 11.2
hs-CRP (lg/mL) 1.4 (0.1–23.0)
a 3.6 (0.4–31.5)
a
Serum creatinine (lmol/L) 95.1 ± 21.7 96.7 ± 20.4
Total cholesterol (mmol/L) 5.2 ± 1.5 5.5 ± 1.4
LDL (mmol/L) 3.1 ± 1.3 3.5 ± 1.3
HDL (mmol/L) 1.3 ± 0.4 1.3 ± 0.3
Triglycerides (mmol/L) 1.8 ± 0.7 1.8 ± 0.9
Lp(a) (mg/dl) 23.4 ± 21.2 19.9 ± 18.7
IL-6 (pg/ml) 1.4 (0.0–15.4)
a 1.8 (0.0–43.3)
a
WBC White blood cells, APTT activated partial thromboplastin time,
PT prothrombin time, ESR erythrocyte sedimentation rate at ﬁrst
hour, hs-CRP high sensitivity C-reactive protein, LDL low density
lipoprotein, HDL high density lipoprotein, IL-6 interleukin-6, Lp(a)
Lipoprotein (a)
a Results are median (range)
Table 3 Ultrasound and histological characteristics of carotid
stenosis
Parameter No. of patients (%) (total n = 66)
Asymptomatic
(n = 42)
Symptomatic
(n = 24)
Grade of stenosis (%)

70–85 18 (42.9) 4 (16.7)
85–95 5 (11.9) 1 (4.2)
95–99 19 (45.2) 19 (79.2)
Morphology of plaques by ultrasound

Fibrous 5 (11.9) 0 (0.0)
Soft 11 (26.2) 12 (50.0)
Calciﬁed 4 (9.5) 3 (12.5)
Mixed 14 (33.3) 9 (37.5)
Non-deﬁned 8 (19.0) 0 (0.0)
Histology classiﬁcation
Fibrous 21 (50.0) 9 (37.5)
UNC 9 (21.4) 3 (12.5)
UC 12 (28.6) 12 (50.0)
Immunohistochemistry for EL
§
A (0–25% cells) 24 (57.1) 7 (29.2)
B( [25% cells) 18 (42.9) 17 (70.8)
UNC ulcerated non-complicated plaques (without intra-plaque hem-
orrhage and/or thrombus), UC ulcerated complicated (with intra-
plaque hemorrhage and/or thrombus), EL-endothelial lipase
 v
2, p = 0.027
 v
2, p = 0.039
§ v
2, p = 0.028
J Neurol (2012) 259:448–456 453
123p = 0.17 for IL-6; p = 0.44 for hsCRP). This might
probably reﬂect the diffuse nature of atherosclerosis that
masks the effect of increased local inﬂammatory molecule
production in unstable HCAP, highlighting the importance
and relevance of localized EL expression at the site of
pathology. Furthermore, this lack of association between
local EL expression in HCAP and IL-6 and hsCRP might
be due to the analysis of the total cohort irrespective of
gender [26], age [27], or routine exercise [28]—factors
with established impact on the plasma levels of inﬂam-
matory molecules. Additionally, the expression of inﬂam-
matory molecules might have been differently affected by
medication—considering pharmacological properties, dos-
age and interactions of the therapeutics, and the duration of
the treatment.
In the present study, there was no signiﬁcant difference
in plasma HDL levels between patients with high (B) and
low (A) EL expression in plaques (mean value in both
groups 1.3 mmol/L, Mann–Whitney U test, p = 0.76).
Importantly, in the study group, 69% of patients were
treated with statins (atorvastatin 19 pts, simvastatin 23 pts,
ﬂuvastatin 3 pts) known to increase HDL plasma levels by
regulating various molecules that participate in reverse
cholesterol transport, such as apo AI [29], scavenger
receptor B type I (SR-BI) [30], or ATP binding cassette A1
(ABCA1) [31]. Furthermore, statins were shown to
decrease EL expression [32, 33]. Considering this and the
fact that patients were treated with various doses of dif-
ferent statins, known to vary in their potency to modulate
HDL plasma levels, it is tempting to assume that the lack of
Fig. 2 HCAP histology and immunostaining of EL and CD163. For
histology, serial sections of HCAP were stained with HE and for
immunohistochemical detection of EL and CD163, with antibodies
against EL and the mononocyte/macrophage marker CD163. A
ﬁbrous plaque (F) is shown in panels a–c: a HE-stained F plaque with
ﬁbrous cap (ﬁlled arrow heads) and necrotic core (asterisk). b EL
staining (red) in the endothelium (empty arrows) and in cells within
the ﬁbrous cap (ﬁlled arrows). c CD163 immunostaining (red). An
ulcerated plaque (UC) is shown in panels d–f: d HE-stained UC
plaque with inﬂammatory inﬁltrate (asterisks) and intra-plaque
erythrocytes (empty arrow heads). e EL immunostaining. f CD163
staining. Scale bar represents 50 lm
Fig. 3 The intensity of EL immunostaining increases with plaque
instability. The intensity of EL immunostaining was determined in
different types of plaques, deﬁned by histology as ﬁbrous plaques (F),
ulcerated non-complicated plaques (UNC), and ulcerated complicated
plaques (UC). Grey columns represent the number of patients
exhibiting low intensity of EL immunostaining (A), whereas black
columns denote those with high intensity of EL immunostaining
(B) in plaques. 79.2% of UC plaques were type B, 50% of UNC
plaques were type B, whereas 66.7% of F plaques exhibited type A
immunostaining. v
2 test, p = 0.004
454 J Neurol (2012) 259:448–456
123association between EL in HCAP and HDL plasma levels
in the present study is partially due to medication. In
addition to statins, angiotensinogen II (AT II) receptor
antagonists (10 pts), as well as angiotensin converting
enzyme inhibitors (33 pts) might, considering the capacity
of AT II to modulate EL expression [34], affect the rela-
tionship between EL in HCAP and HDL plasma levels as
well as between EL in HCAP and inﬂammatory markers.
Interestingly, neither statins nor ACE inhibitors impacted
signiﬁcantly the intensity of EL immunostaining in HCAP
(not shown). Furthermore, increased EL mass in HCAP
does not necessarily have to be accompanied by increased
local EL phospholipase activity, considering reduced
phospholipase activity of various genetic variants [35].
Finally, the relative contribution of EL in HCAP to the
total systemic EL phospholipase activity might be too low
to signiﬁcantly affect HDL plasma levels. Besides, even
serum EL levels were found not to correlate signiﬁcantly
with HDL levels [11, 36].
The results of our study are in line with previous reports
showing no obligatory association between symptomatol-
ogy of carotid disease and histological features of plaque
vulnerability. This might be due to: (1) the lack of strong
uniform criteria for plaque instability, (2) artiﬁcial (labo-
ratory) disruption of the plaque surface, or iii) some
unstable plaques which resolve spontaneously without
causing symptoms [37–39]. In addition, some of the
ischemic events are not caused by the carotid lesion itself,
but rather by embolic material derived from heart and
aorta. Using echocardiography, we could exclude only
some of the patients with suspected cardiac source of
embolism. Moreover, it is known that not only the vul-
nerable plaque makes the patient vulnerable, but also that
the vulnerable environment (e.g., blood prone to throm-
bosis) plays an important role in the overall outcome.
To our knowledge this is the ﬁrst study addressing the
relationship between the intensity of EL immunostaining in
HCAP and the degree of HCAP vulnerability and HCAP-
related symptomatology. The higher EL immunostaining in
vulnerable and symptomatic HCAP suggests a strong
involvement of EL in the local inﬂammatory process, a key
element of plaque destabilization. Whether EL in HCAP is
only a marker or an active causative factor for cerebro-
vascular events and whether EL in HCAP has a prognostic
value for the incidence and velocity of carotid artery re-
stenosis or other cerebro- and/or cardio-vascular events
remains to be examined.
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